{"entity":{"id":"gintemetostat","kind":"drug","name":"Gintemetostat","aka":["KTX-1001"],"tldr":"Gintemetostat is an experimental small molecule from K36 Therapeutics, in phase 1 trials for relapsed or refractory multiple myeloma).","summary":"Gintemetostat (KTX-1001) is a small molecule (oral) from K36 Therapeutics. An oral, selective inhibitor of NSD2 (also called MMSET or WHSC1), which is overexpressed in multiple myeloma with the t(4;14) translocation; it is designed to reduce H3K36me2 levels and reverse oncogenic transcriptional programmes. Its furthest stage is phase 1, for relapsed or refractory multiple myeloma (t(4;14)). ClinicalTrials.gov registers it in one study linked below. NCT05651932 (K36-MMSET-001) recruiting per v2 API, with combination cohorts. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"K36 Therapeutics: k36tx.com","url":"https://www.k36tx.com/"},{"label":"K36 Therapeutics: k36tx.com","url":"https://www.k36tx.com/"},{"label":"K36 Therapeutics: k36tx.com","url":"https://www.k36tx.com/about-ktx-1001"},{"label":"K36 Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05651932"},{"label":"ClinicalTrials.gov: trials of KTX-1001","url":"https://clinicaltrials.gov/search?intr=KTX-1001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["nsd2"],"drugs":[],"companies":["k36-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05651932"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"KTX-1001","modality":"Small molecule (oral)","mechanism":"An oral, selective inhibitor of NSD2 (also called MMSET or WHSC1), which is overexpressed in multiple myeloma with the t(4;14) translocation; it is designed to reduce H3K36me2 levels and reverse oncogenic transcriptional programmes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gintemetostat/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/"}],"company":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/"}],"trial":[{"id":"nct05651932","kind":"trial","name":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","route":"/trials/nct05651932/"}]}}